Biology and Treatment of Malignant Glioma

ONCOLOGY

Volumn 12, Issue 2, 1998, Pages 233-240

  Shapiro, William R ^a   Shapiro, Joan Rankin ^b  

^a Division of Neurology   (United States)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CHLOROETHYL) 3 (2,6 DIOXO 3 PIPERIDYL) 1 NITROSOUREA; ANTINEOPLASTIC AGENT; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; LOMUSTINE; METHYLPREDNISOLONE; MISONIDAZOLE; NITROSOUREA DERIVATIVE; PLATELET DERIVED GROWTH FACTOR; PROCARBAZINE; STREPTOZOCIN;

CANCER GENETICS; CANCER RADIOTHERAPY; CANCER SURGERY; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GLIOBLASTOMA; HUMAN; ONCOGENE; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE;

GLIOMA; HUMANS;

EID: 0031884723     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Mahaley Jr MS, Mettlin C, Natarajan N, et al. National survey of patterns of care for braintumor patients. J Neurosurg 71:826-836, 1989.
2. Shapiro WR, Shapiro JR, Walker RW: Central nervous system, in Abeloff MD, Armitage JO, Lichter AS (eds): Clinical Oncology, pp 851-912. New York, Churchill Livingstone, 1995.
3. Burger PC, Scheithauer BW, Vogel FS: Surgical Pathology of the Nervous System and its Coverings, 3rd ed, pp 193-234. New York, Churchill Livingstone, 1991
4. Daumas-Duport C: Histological grading of gliomas. Curr Opin Neurol Neurusurg 5:924-931, 1992.
5. Shapiro JR, Scheck AC: Brain tumors, in Wolman SR, Sell S (eds): Cytogenetic Cancer Markers, pp 319-368. Totowa, New Jersey, Humana Press, 1997.
6. James CD, Carlborn E, Dumanski JP, et al: Clonal genomic alterations in glioma malignancy stages. Cancer Res 48: 5546-5551, 1988.
7. Ransom DT, Ritland SR, Moertel CA, et al: Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas. Genes Chromosomes Cancer 5: 357-374, 1992.
8. Ohgaki H, Eibl RH, Schwab M, et al: Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Curcinog 8:74-80, 1993.
9. Reifenberger G, Liu L, Ichimura K, et al: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancel Res 53: 2736-2739, 1993.
10. Arnoldus EPJ, Wolters LET, Voormolen JHC, et al: Interphase cytogenetics. A new tool for the study of genetic changes in brain tumors J Neurosurgery 76:997-1003, 1992.
11. von Deimling A, Louis DN, Schramm J, et al: Astrocytic gliomas: Characterization on a molecular genetic basis. Recent Results Cancer Res 135: 33-42, 1994.
12. Sidransky D, Mikkelsen T, Schwechheimer K, et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847, 1992.
13. Ekstrand AJ, Longo N, Hamid ML, et al: Functional characterization of an EGF receptor with a truncated extracellular domain expressed in GBMs with EGFR gene amplification. Oncogene 9:2313-2320, 1994.
14. Weiner HL: The role of growth factor receptors in central nervous system development and neoplasia Neurosurgery 37:179-194, 1995.
15. Van Meyel DJ, Ramsay DA, Casson AG, et al: p53 mutation, expression, and DNA ploidy in evolving gliomas evidence for two pathways of progression. J Natl Cancer inst 86:1011-1017, 1994.
16. von Deimling A, von Ammon K, Schoenfeld D, et al: Subsets of glioblastomas multiforme defined by molecular genetic analysis. Brain Pathol 3:19-26, 1993.
17. Leenstra S, Bijlsma EK, Troost D, et al: Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis. Br J Cancer 70:684-689, 1994.
18. Coons SW, Johnson PC, Shapiro JR: Cytogenetic and flow cytometry DNA analysis of regional heterogeneity in a low grade glioma. Cancer Res 55:1569-1577, 1995.
19. Leenstra S, Troost D, Westerveld A, et al: Molecular characterization of areas with low grade tumor or satellitosis in human malignant astrocytomas. Cancer Res 5:1568-1572, 1992.
20. Scheck AC, Shapiro JR, Coons SW, et al: Biological and molecular analysis of a low grade recurrence of a glioblastoma multiforme Clin Cancer Res 2:187-199, 1995.
21. Strugar JG, Criscuolo GR, Rothbart D, et al: Vascular endothelial growth/permeability factor expression in human glioma specimens: Correlation with vasogenic brain edema and tumor-associated cysts. J Neurosurg 83:682-689, 1995.
22. Shapiro WR. Therapy of adult malignant brain tumors: What have the clinical trials taught us? Semin Oncol 13:38-45, 1986.
23. Nazzaro JM, Neuwelt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73:331-344, 1990.
24. Glantz MJ, Burger PC, Herndon JE, et al: Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas Neurology 41:1741-1744, 1991.
25. Wood JR, Green SB, Shapiro WR: The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6:338-343, 1988
26. Albert FK, Forsting M, Sartor K, et al: Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis Neurosurgery 34:45-61, 1994.
27. Simpson, J.R., Horton J, Scott C, et al: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26:239-244, 1993.
28. Kelly PJ, Hunt C: The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 34:62-67, 1994
29. Walker MD, Alexander E, Hunt WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial. J Neurosurg 49:333-343, 1978.
30. Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980.
31. Walker, MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5:1725-1731, 1979.
32. Shapiro WR, Green SB, Burger PC, et al: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71:1-9, 1989.
33. Deutsch M, Green SB, Strike TA, et al: Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazoie plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16:1389-1396,1989.
34. Gutin SA, Leibel SA, Wara WM, et al: Recurrent malignant gliomas: Survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg 67:864-873, 1987.
35. Loeffler JS, Alexander E, Shea WM, et al: Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 10:1379-1385, 1992.
36. Mehta MP, Masciopinto J, Rozental J, et al: Stereotactic radiosurgery for glioblastoma multiforme: Report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30:541-549, 1994.
37. Curran WJ, Scott CB, Weinstein AS, et al:. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: A report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 11:857-862, 1993.
38. Loeffler JS, Shrleve DC, Alexander E: Radiosurgery for glioblastoma multiforme: The importance of selection criteria. Int J Radiat Oncol Biol Phys 30:731-733, 1994.
39. Green SB, Byar DP, Walker MD, et al: Comparisons of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malig- nant glioma. Cancer Treat Rep 67:121-132, 1983.
40. Shapiro WR, Green SM, Burger PC, et al: A randomized comparison of intra-artenal versus intravenous BCNU, with or without intravenous 5-ftuorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 76:772-781, 1992.
41. Rosenblum, M.K., Delattre JY, Walker RW, Shapiro WR: Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: A pathological study. J Neurooncol 7:269-281, 1989.
42. Hiesiger EM, Green SB, Shapiro WR, et al: Results of a randomized trial comparing intraarterial cisplatin and intravenous PCNU for the treatment of primary brain tumors in adults: Brain Tumor Cooperative Group trial 8420A. J Neurooncol 25:143-154, 1995.
43. Brem H, Piantadosi S, Burger PC, et al:. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012, 1995.
44. Mahaley MS: Neuro-oncology index and review (adult primary brain tumors): Radiotherapy, chemotherapy, immunotherapy, pholodynamic therapy. J Neurooncol 11:85-147, 1991.
45. Cairncross G, Macdonald D, Ludwin S, et al: Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021, 1994.
46. Kim L, Hochberg FH, Thornton AF, et al: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg 85:602-607, 1996.
47. Kondziolka D, Lunsford LD, Martinez AJ: Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult Supratentorial (low-grade) astrocytoma. J Neurosurg 79:533-536, 1993.
48. Laws ER, Taylor WF, Clifton M, Okazaki H: Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 61:665-673, 1984.
49. Berger MS, Deliganis AV, Dobbins J, Keles GE: The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784-1791, 1994.
50. Shaw EG, Daumas-Duport C, Scheithauer BW, et al: Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 70:853-861, 1989.
51. Soffietti R, ChioA, Giordana MT, et al: Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery 24:686-692, 1989.
52. Vertosick FT, Selker RG, Arena VC: Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 28:496-501, 1991.
53. Philippon JH, Clemenceau SH, Fauchon FH, et al: Supratentorial low-grade astrocytomas in adults. Neurosurgery 32:554-559, 1993.
54. Recht LD, Lew R, Smith TW: Suspected low-grade glioma. Is deferring treatment safe? Ann Neurol 31:431-436, 1992.
55. Winger MJ, Macdonald DR, Cairncross JG: Supratentorial anaplastic gliomas in adults: The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 71:487-493, 1989.
56. Taphoorn MJB, Schiphorst AK, Snoek FJ, et al: Cognitive functions and quality of life in patients with low-grade gliomas: The impact of radiotherapy. Ann Neurol 36:48-54, 1994.
57. Burger PC, Rawlings CE, Cox EB, et al: Clnicopathological correlations in the oligodendroglioma. Cancer 59:1345-1352, 1987.
58. Smith MT, Ludwig CL, Godfrey AD, et al: Grading of oligodendrogliomas. Cancer 52:2107-2114, 1983.
59. Ludwig CL, Smith MT, Godfrey AD, et al: A clinicopathological study of 323 patients with oligodendrogliomas. Ann Neural 19: 15-21, 1986.
60. Lindegaard K, Mørk SJ, Eide GE, et al: Statistical analysis of clinicopathological features, radiotherapy, and survival in 170 cases of oligo- dendroglioma. J Neurosurg 67:224-230, 1987.
61. Shaw EG, Scheithauer BW, O'Fallon JR, et al: Oligodendrogliomas: The Mayo Clinic experience J Neurosurg 76:428-434, 1992.
62. Bullard DE, Rawlings CE, Phillips B, et al. Oligodendroglioma: An analysis of the value of radiation therapy. Cancer 60:2179-2188, 1987.
63. Shaw EG, Scheithauer BW, O'Fallon JR, et al: Mixed oligoastrocytomas: A survival and prognostic factor analysis Neurosurgery 34:577-582, 1994.
64. Celli P, Nofrone I, Palma L, et al: Cerebral oligodendroglioma: Prognostic factors and life history. Neurosurgery 35:1018-1035, 1994.
65. Steck PK, Pershouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMACI, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362, 1997.
66. Li J, Yen C, Liaw D, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 275:1943-1947, 1997.